ERAS-801 clinical trials
Also written ERAS-801.
How each study uses ERAS-801 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ERAS-801 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ERAS-801
- 3
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Katmai Pharmaceuticals Inc. (1) · Jonsson Comprehensive Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Anti-EGFR Antibody-drug Conjugate ABBV-637 (1) · Mirzotamab clezutoclax (1) · Temozolomide (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ERAS-801.
- Jul 2027ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG TrialPhase 1 · Jonsson Comprehensive Cancer Center
Studies
Open first, then newest update. How each study uses ERAS-801 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG TrialRecruitingPhase 1Jonsson Comprehensive Cancer CenterNCT07089641Written as EGFR Inhibitor ERAS-801
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT06934889Written as ERAS-801
- A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)Active, not recruitingPhase 1Katmai Pharmaceuticals Inc.NCT05222802Written as ERAS-801
Codes
What other systems call ERAS-801 · ClinicalTrials.gg INT016077
- UNII (FDA) B68F5P9PB7ERAS-801One source FDA
- NCI Thesaurus C187232EGFR Inhibitor ERAS-801One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B68F5P9PB7 | ERAS-801 | One source FDA |
| NCI Thesaurus | C187232 | EGFR Inhibitor ERAS-801 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.